Today, we take an in-depth look at Stemline Therapeutics. The stock has been battered like most of the market in December but received an important FDA approval last week.
The stock enjoys strong analyst support and looks poised to rally once the hugely negative sentiment on the biotech sector ebbs.
A full investment analysis on Stemline is provided in the paragraphs below.
Government! Three fourths parasitic and the other fourth Stupid fumbling." - Robert A. Heinlein, Stranger in a Strange Land
Today, we look at a small 'Tier 3' biotech concern. The stock has